Idorsia plans further job cuts and asset sale in latest cost-saving measures
Idorsia has extended its cash runway into 2025 via an exclusivity fee for global rights negotiations for Tryvio.
Biopharmaceutical Industry
How to adapt to choppy waters in biotech ecosystem
Investment surges, hurdles and emerging innovations in neuroscience
Vertex shares up after full-year product revenue guidance boost
Will the tide turn for the wave of pharma layoffs?
What is the pharmacy of the future?
UAE’s clinical trials space matures with experience from Covid-19
CPHI Europe: Gummies as a drug delivery system could improve compliance
